Navigation Links
TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials

ents discontinued treatment for any reason vs. 73 in the placebo arm.

Most of the rashes seen with TMC125 were mild to moderate in severity, occurred within the first few weeks of treatment and resolved with continued TMC125 treatment. Grade 3 or 4 rash occurred in 1 percent of patients in the TMC125 arm and no patients in the placebo arm.

DUET-1 and -2 Study Design

The DUET studies are double-blind, placebo-controlled, international Phase 3 trials designed to assess the efficacy and safety of TMC125 in treatment- experienced adult HIV-1 patients with documented evidence of NNRTI and PI resistance. Participants were randomized to receive TMC125 200 mg twice daily or placebo, each given in addition to a BR.

In both studies, patient randomization was stratified for enfuvirtide use in the BR (no use, re-use, or first time use), previous darunavir use (used or not), and screening plasma viral load (<30,000 or >=30,000 copies per mL).

Patients with HIV-1 who were eligible for the DUET trials had a viral load of greater than 5,000 copies/mL, were on a stable antiretroviral therapy regimen, and had evidence of at least one NNRTI-resistance-associated mutation, either at screening or from historical resistance tests as well as evidence of three or more primary PI mutations at screening.

TMC125 Expanded Access Program

The expanded access program (EAP) for TMC125 is now open in a number of European countries, Canada and the United States. TMC125 is available to HIV-1 infected adults, at least 18 years old, who have limited treatment options either due to virological failure or intolerance to multiple ARV regimens. Patients must be three-class experienced, having received licensed treatment from each of the three major oral classes of anti-HIV drugs (NRTIs, NNRTIs, and PIs), unable to use currently approved NNRTIs due to resistance and/or intolerance and have received at least two PI-based regimens.

For more about the pro
'"/>




Page: 1 2 3 4

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
5. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
6. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
7. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
8. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
9. Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
10. OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
11. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
Post Your Comments:
(Date:8/3/2015)... N.J. , Aug. 3, 2015 Ortho ... has been named Chief Corporate Brand and Communications ... firm,s executive leadership team, Bouryal will lead the company,s ... builds on its transition to an independent company by ... report to Chairman and Chief Executive Officer Dr. ...
(Date:8/3/2015)... 3, 2015 Cooperative ... military surgical research and top-tier universities for ... to severe wound treatments for critical-care patients ... medicine and tissue-engineered skin substitute advancements.  Biotech ... in focus are Amarantus Bioscience Holdings, Inc. ...
(Date:8/3/2015)...  BioElectronics Corporation (OTC Pink: BIEL), maker of consumer ... Andrew J. Whelan , President will be interviewed by ... at 9am EDT on Wednesday, August 5 th .  ... http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ Mr. Whelan ... company,s flagship product, ActiPatch Therapy, is achieving in the ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2
... Dec. 21, 2010 Generational Equity, a leading ... mergers, acquisitions, strategic growth initiatives, business valuation and ... B-Pharm, Inc. dba Remedies Pharmacy, headquartered in Carrollton, ... closed on October 26, 2010.  Managing Director, Terry ...
... Dec. 21, 2010 Zimmer Holdings, Inc. (NYSE and ... announced that it has completed the acquisition of Beijing ... Zimmer,s presence in the emerging Chinese market.   ... Zimmer family," said David C. Dvorak, President and CEO ...
Cached Medicine Technology:Generational Equity Announces Sale of B-Pharm, Inc. dba Remedies Pharmacy to a Private Investment Group 2Zimmer Finalizes Acquisition of Chinese Orthopaedic Implant Leader Beijing Montagne Medical Device Co., Ltd. 2
(Date:8/3/2015)... Detroit, Mich (PRWEB) , ... August 03, 2015 , ... ... this country has declined, according to a new publication released today by the AAMC ... of black male college graduates over the past three decades, the number of black ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ... to create efficiencies in healthcare information exchange, announced the release of its findings from ... Human Services (HHS) Secretary, WEDI shared survey results and recommendations , ...
(Date:8/3/2015)... ... ... to an opinion piece published July 28 by the Washington Post, the conventional ... loss may not be accurate. While this system may work for some people, the author ... based both on the individual and at what point that person is in their weight ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today announced the ... , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and ... launch of their Readmissions Analytics product was selected as one of four finalists ...
Breaking Medicine News(10 mins):Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2
... and France signed a landmark cooperative treaty here Thursday ... expected by practitioners to help in the fight against ... cooperate in academic and clinical TCM research, setting new ... practice and developing new TCM products, said the document ...
... city's eastern fringe towards the airport, a signboard on the ... by Maneka Gandhi's People for Animals (PFA). ... day comes true. This sprawling pound aims to restore the ... focuses on anti-rabies vaccination for the canines. ,"We ...
... can prevent [chronic diseases], more people can live longer.',Rapid advances ... are bringing// closer the time when many people can achieve ... Dr. Pascal Goldschmidt, dean of the University of Miami Miller ... we will see diagnostic tools and therapies that will change ...
... in Los Angeles, it was reported that AIDS cases have ... Jaffe, a professor of medicine at Oxford University in England, ... ,He also called for a new approach to ... emphasized on the scientific approach rather than moral and religious ...
... women have been asked to keep a strict watch on ... , The appeal has come from UK’s government watchdog group ... , According to them, one in every seven women ... pregnancy. This refers also to the ‘baby blues’ that quite ...
... it is possible to use a resin filter to ... infected animal, //a finding that has major implications for ... associated with variant Creutzfeldt-Jakob disease, mad cow disease, scrapie ... transfusions. ,Dr. Ruben Carbonell, Frank Hawkins Kenan ...
Cached Medicine News:Health News:An Anti-rabies Campaign With Bite 2Health News:An Anti-rabies Campaign With Bite 3Health News:Genetics Might Engineer Path to Successful Aging 2Health News:'Baby Blues’-no Tiny Proble 2Health News:Researchers Develop Resin Beads That Capture Mad Cow Disease Agent From Blood 2
Speculum can be used for any type of eye surgery. Arms of speculum lie flat due to joint between blade and arms. Features quick locking mechanism....
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Fenestrated blades with screw-controlled spread. Dull finish. Blades: 15 mm....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: